Regulatory Aspects of Bioactive‐Based Nanocarriers
Bibliographic record
Abstract
Nanotechnology has revolutionized drug delivery and biomolecular targeting, offering heightened efficacy and reduced off-target toxicity, particularly in cancer treatment. The emergence of nanopharmaceuticals presents a promising avenue for enhancing existing drugs’ safety and efficacy while expediting the drug discovery process. However, the evaluation of nanopharmaceuticals poses unique challenges due to their distinct physical, chemical, and biological properties. This chapter outlines guidelines for the evaluation of nanopharmaceuticals, emphasizing the need for standardized assessments of quality, safety, and efficacy to facilitate regulatory approval and industry innovation. The global regulatory landscape for nanopharmaceuticals varies widely, with different regions adopting diverse approaches. The European Union, United States, United Kingdom, Canada, Australia, China, and India each exhibit distinct regulatory frameworks and initiatives for overseeing nanotechnology applications in pharmaceuticals. Despite notable progress, gaps in regulation persist, hindering the translation of nanomedicine research into marketable products. Addressing these regulatory challenges requires international collaboration and coherence among regulatory agencies to ensure the safe and effective development of nanopharmaceuticals. Without clear guidance and leadership, the full potential of nanotechnology in medicine may remain unrealized, jeopardizing substantial investments and impeding progress in healthcare innovation.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.004 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.002 |
| Scholarly communication | 0.003 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".